Topic - roche

Subscribe to this topic via RSS or ATOM
Related Stories
  • DNA alternative to Pap smear sparks medical debate

    A high-tech screening tool for cervical cancer is facing pushback from more than a dozen patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: the Pap smear.

  • DNA alternative to Pap smear sparks medical debate

    A high-tech screening tool for cervical cancer is facing pushback from more than a dozen patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: the Pap smear.

  • Roche enjoys strong profit, expects growth in 2014

    Swiss drug maker Roche saw its full-year profits boosted by strong demand for its cancer medicines and diagnostic tests used by clinical laboratories, the company reported Thursday.

  • Novartis tries to make UK hospitals use $1000 drug

    Drug maker Novartis is taking legal action in Britain to make state-run hospitals use an eye drug that costs about 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

  • California-based Genentech, Inc., makes the cancer drug Avastin. A new analysis raises fresh questions about the effectiveness and risks of Avastin. (Associated Press)

    FDA panel again nixes Avastin for breast cancer

    A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the government to remove its endorsement from the drug.

  • FDA panel: Revoke drug's breast cancer approval

    A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the government to remove its endorsement from the drug.

  • Experts veto Avastin as a breast cancer treatment

    A panel of cancer experts said Tuesday that the government should remove its endorsement of Roche's drug Avastin for breast cancer, after follow-up studies failed to show benefits for patients.

  • FDA says breast cancer drug did not extend lives

    Follow-up studies of a Roche breast cancer drug showed that it failed to extend the lives of patients, federal health scientists said Friday, opening the door for it to be potentially withdrawn for use in treating that disease.

  • FDA says breast cancer drug did not extend lives

    Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed that it failed extend patient lives, opening the door for it to be potentially withdrawal for use in treating that disease.

More Stories →

Happening Now